Keyphrases
Putative Drug Targets
100%
Aurora Kinase A (AURKA)
100%
Cutaneous T-cell Lymphoma
100%
Lymphoma Cells
33%
Apoptosis
16%
Non-Hodgkin Lymphoma
16%
Cell Proliferation
16%
Immunohistochemistry
16%
Patient Samples
16%
Western Blotting
16%
Serine-threonine Kinase
16%
Poor Prognosis
16%
Novel Genes
16%
Heterogeneous Groups
16%
Therapeutic Value
16%
Cell Cycle Arrest
16%
Advanced Stage
16%
Novel Pathways
16%
G2 Phase
16%
Gene Expression Array
16%
Therapeutic Modalities
16%
Aurora Kinase Inhibitor
16%
Quantitative Reverse Transcriptase PCR
16%
Overexpressed Genes
16%
Cutaneous Lymphoma
16%
Medicine and Dentistry
Cutaneous T Cell Lymphoma
100%
Aurora A Kinase
100%
Cutaneous T-Cell Lymphoma Cell Line
50%
Immunohistochemistry
25%
Non-Hodgkin Lymphoma
25%
Programmed Cell Death
25%
Cell Proliferation
25%
Western Blot
25%
Protein Serine Threonine Kinase
25%
Gene Expression
25%
Quantitative Reverse Transcription Polymerase Chain Reaction
25%
Cell Cycle Arrest
25%
Therapeutic Modality
25%
Expression Array
25%
Cell Cycle Checkpoint
25%
G2 Phase
25%
Cutaneous Lymphoma
25%
Immunology and Microbiology
T Cell
100%
Kinase A
100%
Cutaneous T-Cell Lymphoma Cell Line
50%
Cell Proliferation
25%
Western Blot
25%
Quantitative Reverse Transcription Polymerase Chain Reaction
25%
Gene Expression
25%
Cell Cycle Arrest
25%
Cell Cycle Checkpoint
25%
Cell Cycle G2 Phase
25%
Serine
25%
Programmed Cell Death
25%
Threonine
25%
Pharmacology, Toxicology and Pharmaceutical Science
Cutaneous T Cell Lymphoma
100%
Aurora A Kinase
100%
Western Blot
16%
Nonhodgkin Lymphoma
16%
Protein Serine Threonine Kinase
16%
Expression Array
16%
Skin Lymphoma
16%
Reverse Transcriptase
16%